A Comprehensive Guide to RGCC Testing & Therapy Implementation

Introduction to RGCC Testing & Therapies

RGCC (Research Genetic Cancer Center) offers cutting-edge genetic, immune, and molecular testing for personalized cancer treatment, as well as advanced cellular and gene-based therapies. These tools help practitioners tailor treatments based on individual tumor biology, immune response, and genetic markers.

RGCC Testing

Cancer Screening & Monitoring Tests

These tests detect circulating tumor cells (CTCs) and their biological markers to track cancer presence, aggressiveness, and treatment response.

Onco-D-Clare (Cancer Screening Test)

• Uses machine learning and molecular analysis to detect cancer before symptoms arise.
• Evaluates the expression of 90+ genes in blood samples.
• High accuracy (≈93%) in differentiating cancerous and healthy cells.

OncoTrace (Baseline & Follow-up CTC Test)

• Detects all cancer types (except CNS cancers).
• Provides a baseline measurement of CTC levels before treatment.
• Tracks treatment response and long-term monitoring for recurrence.
• Assesses stemness markers, indicating cancer aggressiveness and resistance.

OncoTrail RGCC (Targeted Cancer Monitoring)

• Used for specific cancer types (Breast, Colon, GI, Lung, Melanoma, Prostate, Sarcoma).
• Monitors known cancers post-treatment to detect recurrence.
• More precise than OncoTrace for primary tumor origin detection.

OncoCount (CTC Enumeration for Follow-Up Care)

• Measures only the number of circulating tumor cells (no phenotyping).
• Effective for tracking treatment response over time.

MetaStat (Metastasis Risk & Site Prediction)

• Identifies markers predicting the likelihood of secondary tumors.
• Determines potential metastasis sites (Lung, Liver, Bones, Brain, etc.).

Drug & Natural Compound Sensitivity Testing

These tests help identify the most effective chemotherapy agents and natural therapies for a patient’s cancer.

Onconomics Plus (Comprehensive Drug & Natural Therapy Test)

• Evaluates over 50 chemotherapy drugs, 60 targeted drugs, and 50 natural compounds.
• Determines which drugs and natural substances will be most effective.
• Includes tumor gene expression profiling and resistance markers for treatment planning.

Onconomics (Chemotherapy Sensitivity Testing)

• Tests chemotherapy effectiveness only (no natural compounds).
• Helps refine drug selection to maximize effectiveness & minimize toxicity.

Onconomics Extracts+ (Comprehensive Natural Therapy Test)

• Evaluates natural compounds for anti-cancer effects.
• Tests for inhibition of growth factor receptors, immune modulation, and apoptosis activation.

Onconomics Extracts (Basic Natural Therapy Test)

• Tests effectiveness of 50+ natural substances for anti-cancer activity.
• Measures how substances influence cancer signaling pathways, immune response, and cell death mechanisms.

ChemoSNiP (Pharmacogenomics Test for Drug Metabolism)

• Identifies genetic variations that affect a patient’s response to chemotherapy drugs.
• Helps select least toxic, most effective drugs.

Immune System & Advanced Genetic Testing

Immune-Frame (Immune System Analysis for Cellular Therapies)

• Evaluates immune health to determine eligibility for RGCC cellular therapies.
• Measures immune suppression, dendritic cell activity, and inflammatory markers.

ArrayCGH RGCC (Genetic Testing for Tumor Origin)

• Identifies genetic abnormalities and chromosomal changes in cancer cells.
• Useful when the primary tumor origin is unknown.

CAMBISeq (Next-Generation Sequencing for Targeted Therapy Selection)

• Identifies mutations targeted by FDA-approved therapies & clinical trials.
• Helps determine if immunotherapy or precision medicine may be effective.

RGCC Therapies

Gene Therapy-Based Cancer Treatments

Q-Restrain (SOT Therapy) – Gene Silencing Cancer Therapy

• RNA interference technology that silences cancer cell replication.
• High specificity (98%), affecting only cancer cells, not normal tissues.
• Remains active for 6 months, preventing tumor progression.
• Not suitable for large tumors (>5cm) or CNS cancers.

Cellular Immunotherapy Treatments

Dendritic Cell Therapy (DC Therapy)

• Enhances the immune system’s ability to recognize and attack cancer cells.
• Uses dendritic cells harvested from the patient to trigger a stronger immune response.
• Administered as 3 IV doses over 3 weeks.
• Effective for solid tumors, but not blood cancers or CNS tumors.

Tumor Fragment Vaccine Preparation (ATA Therapy)

• Uses fragments of a patient’s own tumor cells to stimulate immunity.
• Administered as 6 injections over 9 weeks.
• Effective for early-stage cancers with intact immune function.

Clavic-Q-Re (Adoptive Cellular Therapy)

• Combines macrophages, NK cells, dendritic cells, T cells, and plasma cells to attack cancer.
• Creates a multi-dimensional immune response.
• Used for hematologic and solid tumors but not for CNS cancers.

Clinical Implementation Guide

Patient Selection Criteria

• Who is a candidate?
  • Patients with confirmed cancer diagnoses (solid or hematologic).
  • Patients seeking alternative, adjunctive, or precision medicine approaches.
  • Must have an adequate immune system for immunotherapy options.
• Contraindications for RGCC Therapies
  • Active autoimmune diseases (may worsen with immune stimulation).
  • Recent chemotherapy, radiation, or immunosuppressive therapy.
  • Pregnancy (therapies not tested for fetal safety).
  • Advanced cachexia or frailty (poor response expected).

Testing & Therapy Administration Procedures

• Testing Process
  • Blood samples are collected for CTC analysis, genetic testing, and drug sensitivity profiling.
  • Results guide therapy selection and treatment planning.
• Therapy Administration
  • Q-Restrain: Single-dose IV, active for 6 months done every 4 months for the 1^st year of therapy.
  • Dendritic Cell Therapy: 3 doses, spaced weekly.
  • Tumor Fragment Vaccine: 6 injections over 9 weeks.
  • Clavic-Q-Re Therapy: 3 doses, spaced biweekly.

Monitoring & Follow-Up Care

• Post-Treatment Follow-Ups
  • CTC testing every 4 months to track cancer recurrence.
  • Regular immune function assessments to evaluate therapy impact.
• Adjustments & Additional Treatments
  • Patients with persistent CTCs may require repeat or additional supportive therapies.
  • Lifestyle modifications (anti-inflammatory diet, detoxification) are encouraged for long-term outcomes.